All About Esophageal Cancer

Autor: OncoLink Team
Última Vez Revisión: 8 de abril de 2019

What is the esophagus?

The esophagus is a muscular tube which connects the mouth to the stomach. The wall of the esophagus is composed of a series of muscles that are responsible for peristalsis, or the muscular motion that moves food down the throat into the stomach. The esophagus is lined with two layers of tissue known as the mucosa and submucosa. This is where most cancers of the esophagus develop. The esophagus is a long tube, with an average length of 25 cm. The throat (or pharynx) is continuous with the esophagus, and although the two are indistinguishable, the esophagus is thought to start a few centimeters below the thyroid cartilage (Adam's apple). The esophagus travels down through the chest, between the lungs. It then passes through a hole in the diaphragm to connect with the stomach. There is a ring of muscle, also known as the lower esophageal sphincter, between the stomach and esophagus, which prevents food and stomach acid from going back up into the esophagus.

What is esophageal cancer?

Normally, cells in the body will grow and divide to replace old or damaged cells in the body. This growth is highly regulated, and once enough cells are produced to replace the old ones, normal cells stop dividing. Tumors occur when there is an error in this regulation and cells continue to grow in an uncontrolled way. Tumors can either be benign (not cancer) or malignant (cancer). Although benign tumors may grow in an uncontrolled fashion sometimes, they do not spread beyond the part of the body where they started and do not invade into surrounding tissues. Malignant tumors, however, will grow in such a way that they invade and damage other tissues around them. They also may spread to other parts of the body, which is called metastasis. 

Cancers are described by the type of cells from which they arise.The vast majority of esophageal cancers develop from the inner lining (mucosa) of the esophagus. The lining of the esophagus is somewhat unique: it changes as it goes from the throat to the stomach. In the upper (proximal) esophagus, the lining of the esophagus resembles the lining of the throat, made up of squamous cells. Hence, when cancers develop in this region, they are usually squamous cell carcinomas. In the lower (distal) esophagus, the more common type of cancer is called adenocarcinoma, which is what the cancer is called when it develops from an area of the lining that contains glands.

In addition to invasive cancers, patients are sometimes diagnosed with precancerous lesions, called carcinoma-in-situ. These precancerous lesions can be seen prior to the development of either squamous cell carcinoma or adenocarcinoma. Carcinoma-in-situ occurs when the lining of the esophagus undergoes changes similar to cancerous changes without any invasion into the deeper tissues. Hence, while the cells themselves have cancer-like qualities, there has been no spread or invasion by the cancer cells. Another type of lesion that is considered to be a precursor to cancer itself is called Barrett's esophagus, which is explained in depth below.

What causes esophageal cancer and am I at risk?

According to the American Cancer Society, there are about 17,650 news cases of esophageal cancer diagnosed annually. This represents about 1% of all cancer in the US. However, esophageal cancer is more common in other parts of the world including China, India, Iran and southern Africa. Most individuals are diagnosed in their 50s or 60s. Esophageal cancer also impacts more men than women. 

In the past, the vast majority (85%) of the esophageal cancers diagnosed were squamous cell cancers that occurred in the upper esophagus. Today that number is less than 50% of esophageal cancers. Risk factors for this type of cancer include smoking and alcohol use. Although both are thought to be independent risk factors (meaning they can cause cancer on their own, with smoking's risk being the higher), there seems to be a synergistic effect, when both are combined, for the development of esophageal cancer. In other words, people that both smoke and drink heavily are at an exceptionally high risk to develop esophageal cancer when compared to non-smokers and non-drinkers. The rate of esophageal adenocarcinomas has grown due to an increase in Barrett’s esophagus (see below). 

Other risk factors for esophageal cancer include obesity, eating a diet high in processed meats, HPV and certain workplace exposures to nitrosamines, asbestos fibers, and petroleum products. Achalasia, which is a condition where there is ineffective peristalsis (movement) in the esophagus, as well as caustic esophageal injury, from lye ingestion, can increase the risk of esophageal cancer. Some experts believe a history of bulimia, which chronically exposes the esophagus to stomach contents, may also be a risk factor.

Esophageal cancer may be associated with several genetic syndromes including Tylosis with non-epidermolytic Palmoplantar Keratoderma, Howel Evans’ syndrome, familial Barrett’s esophagus, Bloom syndrome and Fanconi anemia. If you have any of these syndromes, you will likely need earlier and more frequent screening for esophageal cancer. You may also want to talk with your healthcare team about genetic counseling and testing.

Barrett’s Esophagus

In recent years the number of adenocarcinomas has been on the rise. These are now the most common type of esophageal cancer seen. Adenocarcinomas of the esophagus tend to involve the lower part of the esophagus. Adenocarcinoma almost always arises in the setting of Barrett's esophagus. 

Barrett's esophagus is caused by chronic irritation due to stomach acid. This happens due to a defect in the lower esophageal sphincter, which separates the stomach from the esophagus. This sphincter is located at approximately the level of the diaphragm. When the sphincter is dysfunctional, acid can reflux, or pass from the stomach into the esophagus. This condition is commonly known as gastroesophageal reflux disease or GERD. This can result in heartburn, bloating, loss of appetite, and stomach pain. Additionally, some people complain of chronic cough from the reflux due to irritation of the voice box from the acid reflux. Patients with chronic GERD are at risk for developing Barrett's esophagus and thus are at higher risk for developing adenocarcinoma of the esophagus. It is not clear if GERD outside the setting of Barrett's esophagus increases the risk of esophageal cancer, though it appears a long or severe history of reflux may increase the risk of esophageal cancer. There are several conditions, which can cause or worsen GERD, including a condition known as a hiatal hernia, where portions of the stomach herniate or improperly move through the diaphragm into the chest, causing sphincter dysfunction and resulting reflux. Additionally, obesity, smoking, and certain foods such as coffee and chocolate may potentially worsen reflux.

Barrett's esophagus is diagnosed by endoscopy, which is a procedure that uses a fiberoptic camera to look down into the esophagus. A gastroenterologist usually performs this test and if any suspicious lesions are seen, they can be biopsied during the endoscopy. Adenocarcinoma of the esophagus is thought to develop from Barrett's esophagus due to further carcinogenic changes in the abnormal lining.

Certain genetic conditions that cause increased acid secretion, such as Zollinger-Ellison syndrome, may increase the risk of adenocarcinomas of the esophagus. Although pharmaceutical agents for the prevention of acid secretion (histamine blockers, proton pump inhibitors) can be effective for the prevention of GERD symptoms, there is no proof that they decrease the incidence of Barrett's esophagus. Surgical manipulation of the esophageal sphincter, making it more difficult for acid to reach the esophagus, may lead to regression, though again, this is unproven. The most important recommendation for someone with Barrett's esophagus is active monitoring (see more about monitoring recommendations in the screening section below).

How can I prevent esophageal cancer?

Because of the link between tobacco and alcohol use and esophageal cancer, avoiding these can reduce your risk of esophageal cancer. It is important to eat a balanced diet, avoiding processed meats. Try to maintain a healthy body weight and exercise regularly. If you are experiencing GERD symptoms, talk to your healthcare provider about treatment options to prevent developing Barrett’s esophagus.

What screening tests are used for esophageal cancer?

There are no screening recommendations and no specific screening test that exists for squamous cell carcinoma of the esophagus. However, screening and surveillance is very important in patients with Barrett's esophagus (BE), to ensure that it does not progress to adenocarcinoma. It has been estimated that there is approximately a 0.2%-2% risk annually of someone with Barrett's esophagus developing esophageal cancer, or a 10% lifetime risk.

The "gold standard" for diagnosis of BE is endoscopy and biopsy. The best way to ensure that Barrett's esophagus causes no problems is repeat evaluations through biopsy via endoscopy. The primary goal of endoscopy is to detect dysplasia early. Although Barrett's esophagus, by definition, is when the lining of the esophagus is abnormal, there can be varied levels of "abnormal". This is graded in terms of dysplasia, which is a term that refers to how likely the Barrett's esophagus is to progress to cancer. In patients without dysplasia, but just simple replacement of normal esophageal lining with stomach lining, endoscopy is recommended every two to three years. In patients with mild or low-grade dysplasia, at least two endoscopies should be done six months apart, then yearly if those are OK. Patients with Barrett's esophagus with high grade dysplasia should be followed by endoscopy every 3 months, as these are considered premalignant changes that have a high likelihood of progressing to cancer. Areas of dysplasia can be treated during endoscopy. Ablative techniques exist, such as with a laser. Photodynamic therapy can be used to treat high-grade lesions using a compound to sensitize tumors to a specific wavelength of light, followed by light exposure to the tumor. Endoscopic resection of an involved portion of mucosa can also be used.

What are signs of esophageal cancer?

The most common sign of esophageal cancer is trouble swallowing. This is called dysphagia. It is the sense that food is stuck in the throat or chest. You may also feel like you are choking. Swallowing may also become painful. Dysphagia can often lead to significant weight loss as well. Other symptoms include:

  • Pain or burning in the chest.
  • A cough that won’t go away.
  • Vomiting.
  • Hiccups.
  • Esophageal bleeding leading to black tarry stools and anemia.

How is esophageal cancer diagnosed?

Anyone with trouble swallowing as described above should undergo a work-up to ensure the symptoms are not from esophageal cancer. Your provider will perform a physical exam and order diagnostic tests. Initial tests may include a barium swallow. During this procedure, the individual swallows barium to allow visualization of the contours of the esophagus on x-rays. Generally, the esophagus is smooth. If there is a defect in the smooth contour of the esophagus, this may suggest a cancer. Another test commonly performed is endoscopy. An endoscope is a narrow, flexible tube with an attached tiny camera that allows a provider to see inside the esophagus. It is inserted through down the throat and into the esophagus and eventually the stomach. Through endoscopy, the location of the abnormality, the presence or absence of bleeding, and the amount of obstruction can all be seen. A biopsy can also be performed during endoscopy. Once a biopsy is performed, the pathologist can determine if there is esophageal cancer, and whether it is adenocarcinoma or squamous cell carcinoma. Endoscopic ultrasound can also be performed during endoscopy. This can assist the provider in determining size of the tumor as well as if nearby lymph nodes are involved. 

Your provider may also order other tests to assist in the diagnosis of esophageal cancer including a CT scan, MRI, and/or PET scan to evaluate if the cancer has spread as well as blood tests to check for anemia and liver functioning. 

How is esophageal cancer staged?

After all of these tests are performed, the stage of the cancer can be determined. The staging of a cancer describes how much cancer has grown within the esophagus as well as whether it has spread. This is extremely important in terms of what treatment is offered to each individual patient. The staging system used for esophageal cancer is designed to describe the extent of disease within the esophagus, in the surrounding lymph nodes, and distantly. 

The staging system used to describe esophageal tumors is the "TNM system", as described by the American Joint Committee on Cancer. The TNM systems are used to describe many types of cancers. They have three components: T-describing the extent of the "primary" tumor (the tumor in the esophagus itself); N-describing the spread to the lymph nodes; M-describing the spread to other organs (i.e.-metastases). The staging for esophageal cancer also includes G- histologic grade (how the cells appear under the microscope). The location of the tumor is also considered in squamous cell esophageal cancers. There is also a separate stage grouping (ypTNM) that is assigned in patients who have received pre-operative treatment. The T, N, M and G are combined to come up with a stage from 0-IV, with IV being the most advanced. 

The staging system is very complex. The entire staging system is outlined at the end of this article. Though complicated, the staging system helps healthcare providers determine the extent of the cancer, and in turn, make treatment decisions for your cancer. 

How is esophageal cancer treated?

The treatment chosen for a person with esophageal cancer is greatly dependent on two main factors: the extent of the cancer and general health condition of the individual. In people who have very early stage disease that has not spread to lymph nodes or deep into the esophagus, surgery alone may be appropriate. Certain very early tumors, limited to the submucosa (the superficial layer of the esophagus), may be treated with endoscopic resection.

More commonly, people present with advanced stage disease because symptoms often develop only after the tumor has grown to a large size or has spread. Therefore, there is often a large amount of tumor present before cancer treatment can even begin. There are a number of different modalities that can be used to treat esophageal cancer including surgery, radiation, and chemotherapy. However, in people who can tolerate it, combined modality treatment with surgery, radiation and chemotherapy is preferred.

Surgery

Surgery, including removing the esophagus (called an esophagectomy), is a very aggressive procedure. You need to be in good health to be considered for such a procedure.

There are several different surgical procedures to remove the esophagus. However, generally the esophagus is removed either using an incision through the ribs and abdomen or the neck and abdomen. When the esophagus is removed, the stomach is pulled up into the chest to keep the passageway for food intact. Not only is there a risk of infection and bleeding from the surgery itself, but the recovery period after surgery can be difficult. Additionally, there is the risk of a leak forming at the new connection that is formed between the stomach and the remaining portion of the esophagus (known as an anastamosis). This can result in further surgery and potentially lead to very serious complications. In advanced esophageal cancer, there is still a high failure rate with surgery alone. These failures occur both locally (in the region of the primary tumor or regional lymph nodes) or distantly (from metastatic spread of cancer through the bloodstream). Many studies have looked into adding chemotherapy and radiation therapy to esophagectomy to attempt to add to the cure rate. Though the results of these studies are somewhat mixed, it is thought that both radiation and chemotherapy add a benefit. Therefore, radiation therapy (for local tumor control) and chemotherapy (for distant control as well as to improve the effectiveness of radiation therapy) is almost always recommended either before or after the surgery.

Radiation

Radiation therapy uses high energy x-rays to kill cancer cells. It does this by damaging the DNA in tumor cells. Normal cells in our body can repair radiation damage much quicker than tumor cells, so while tumor cells are killed by radiation, many normal cells are not. This is the basis for the use of radiation therapy in cancer treatment. Radiation is delivered using large machines that produce the high energy x-rays. After radiation oncologists set up the radiation fields ("radiation fields" are the areas of the body that will be treated by radiation), treatment is begun. Radiation is given 5 days a week for approximately 5-7 weeks at a radiation treatment center. The treatment takes just a few minutes each day and is completely painless. It is designed to kill tumor cells in the area that is at risk to contain cancer cells, whether it is in the esophagus or the regional lymph nodes. Typical side effects mainly include a sore throat, skin irritation (resembling a sunburn), and fatigue.

Chemotherapy

Chemotherapy is defined as medications that are used to kill tumor cells. The large advantage in using chemotherapy is that it travels throughout the entire body. Hence, if some tumor cells have spread outside of what surgery or radiation can treat, they can potentially be killed by chemotherapy. The additional important benefit from chemotherapy in the treatment of esophageal cancer is that it works with radiation, resulting in killing of more cancer cells. Similar to radiation, some normal cells are damaged during chemotherapy, resulting in side effects. The exact side effects depend on which type of chemotherapy is used, though fatigue, some nausea, and a decrease in blood counts can result from commonly used chemotherapy agents.

There is some debate as to the optimal order in which to deliver these treatments to the esophagus. Different institutions may vary the order in which they use these three modalities in the attempt to cure esophageal cancer. Many will use radiation therapy combined with chemotherapy pre-operatively (prior to surgery).The advantage of using chemotherapy and radiation together is that it often results in the decrease in the size of the tumor that needs to be removed. However, the toxicity from combining radiation with chemotherapy can cause more side effects than if given alone. It is very important for people to maintain their nutrition so they can heal well in anticipation of surgery, which usually takes place around 4-8 weeks after chemoradiation. Surgery after chemotherapy and radiation appears to improve the local control further. However, some centers recommend post-operative treatment. The main advantage of this method is that surgery can be performed in an unirradiated field, allowing for a better surgical technique. Surgical removal of the entire tumor is ideal for the treatment of esophageal cancer

In some cases, the person is too sick to undergo surgery, or may choose not to undergo surgery. In these cases, a combined, concurrent use of chemotherapy with radiation therapy is usually employed. This method has been proven better than radiation alone, and some think it can reach cure rates comparable to surgery, however this is still being studied.

The combined use of radiation therapy and chemotherapy has toxicities as well; mainly irritation of the esophagus making it extremely painful and hence difficult to swallow towards the end of treatment. Some people are too sick to tolerate combined treatment and are treated with radiation or chemotherapy alone.

Medications commonly used in the treatment of esophageal cancers both pre/post operatively, in concert with radiation or without surgery include, paclitaxel, carboplatin, fluorouracil, capecitabine, oxaliplatin, cisplatin, irinotecan, paclitaxel, leucovorin, and docetaxel. These medications are used in various combination regimens based on the staging and subtype of the cancer.

Advanced esophageal cancer is treated with chemotherapy using single agents or a combination of agents, including paclitaxel, carboplatin, cisplatin, fluorouracil, irinotecanepirubicincapecitabine, and docetaxel

In more advanced, recurrent or metastatic esophageal cancers, you may also be tested for certain biomarkers. These include HER2, MSI, MMR, and PD-L1. The presence of these tumor markers may indicate the use of targeted therapy to treat the cancer. These medications include, trastuzumab, ramucirumab, and pembrolizumab.

Supportive Care

Individuals with esophageal cancer can also be treated with techniques to help alleviate symptoms associated with their disease in the event that they are too sick to undergo radiation or chemotherapy. Advanced esophageal cancer that is incurable often leaves the patient with difficulty swallowing or unable to swallow at all. Chest pain and bleeding are other common symptoms that can require palliation (treatment to relieve symptoms, not necessarily treat the cancer). Radiation therapy is often used to achieve palliation, with varying success; especially with obstruction - studies have reported improvement in swallowing in approximately 80% of patients. Mechanical stents can be placed, a "balloon" used to temporarily open the esophagus, or laser removal of tumor can be attempted. These can achieve symptom relief quicker, though they have their risks and are only temporary measures.

As different treatments may be effective in treating a patient's cancer, it is good to be well-informed. Esophageal cancer is treated by a multidisciplinary team that includes: medical oncologists, surgical oncologist, radiation oncologist, advanced practice providers, gastroenterologist and nutritionist. The medical oncologist often leads the team with the goal to maximize chance of cure and function after treatment.

Clinical Trials

There are clinical research trials for most types of cancer, and every stage of the disease. Clinical trials are designed to determine the value of specific treatments. Trials are often designed to treat a certain stage of cancer, either as the first form of treatment offered, or as an option for treatment after other treatments have failed to work. They can be used to evaluate medications or treatments to prevent cancer, detect it earlier, or help manage side effects. Clinical trials are extremely important in furthering our knowledge of disease. It is through clinical trials that we know what we do today, and many exciting new therapies are currently being tested. Talk to your provider about participating in clinical trials in your area. You can also explore currently open clinical trials using the OncoLink Clinical Trials Matching Service.

Follow-Up Care and Survivorship

Follow- up care after treatment for esophageal cancer varies greatly based on the stage of the tumor and the treatment(s) received. In general, you can expect frequent follow up visits with your health care providers; typically, every 3-6 months for the first two years, then every 6-12 months for the next three years and then annually. These follow-up visits may also include laboratory monitoring. For individuals with early stage disease who were treated with endoscopic resection or ablation, you should have an upper endoscopy every 3 months for the first year, every six months for the second year and then annually. Again, depending on initial stage of disease and treatment you may also need imaging (CT scan of the chest and abdomen) as part of your follow-up care.

Fear of recurrence, ongoing swallowing and nutrition challenges, relationship changes and sexual health, financial impact of cancer treatment, and employment issues are common emotional and practical issues experienced by esophageal cancer survivors. Your healthcare team can identify resources for support and management of these challenges faced during and after cancer.

Cancer survivorship is a relatively new focus of oncology care. With some 15 million cancer survivors in the US alone, there is a need to help patients transition from active treatment to survivorship. What happens next, how do you get back to normal, what should you know and do to live healthy going forward? A survivorship care plan can be a first step in educating yourself about navigating life after cancer and helping you communicate knowledgeably with your healthcare providers. Create a survivorship care plan today on OncoLink.

Resources for More Information

Esophageal Cancer Awareness Association: Offers help and advice to patients, caregivers, survivors, family members affected by the disease.

Esophageal Cancer Action Network (ECAN): Provides information and support for patients and caregivers and public awareness.

ACOR Esophageal Cancer Group: Email support group for esophageal cancer patients and families.

Appendix: Complete Esophageal Cancer Staging

American Joint Commission on Cancer (AJCC); 8th ed., 2017

T (Primary Tumor)

Description

TX

Primary tumor cannot be assessed

T0

No evidence of primary tumor

Tis

High-grade dysplasia, defined as malignant cells confined to the epithelium by the basement membrane

T1

Tumor invades the lamina propria, muscularis mucosae, or submucosa

T1a

Tumor invades the lamina propria or muscularis mucosae

T1b

Tumor invades the submucosa

T2

Tumor invades the muscularis propria

T3

Tumor invades adventitia

T4

Tumor invades adjacent structures

T4a

Tumor invades the pleura, pericardium, azygos vein, diaphragm, or peritoneum

T4b

Tumor invades other adjacent structures, such as the aorta, vertebral body, or airway

 

N (Regional Lymph Nodes)

Description

NX

Regional lymph nodes cannot be assessed

N0

No regional lymph node metastasis

N1

Metastasis in one or two regional lymph nodes

N2

Metastasis in three to six regional lymph nodes

N3

Metastasis in seven or more regional lymph nodes

 

M (Distant Metastasis)

Description

M0

No distant metastasis

M1

Distant metastasis

 

G (Histologic Grade)

Description

GX

Grade cannot be assessed

G1 

Well differentiated

G2

Moderately differentiated

G3

Poorly differentiated, undifferentiated

 

Location

Squamous Cell Caricnoma (only) Location Criteria*

X

Location unknown

Upper

Cervical esophagus to lower border of azygos vein

Middle

Lower border of azygos vein to lower border of inferior pulmonary vein

Lower 

Lower border of inferior pulmonary vein to stomach, including the gastroesophageal junction

*Location is defined by the position of the epicenter of the tumor in the esophagus

Squamous Cell Carcinoma Stage Grouping

Clinical Stage Grouping (cTNM)

cT

cN

M

Stage 0

T1s

N0

M0

Stage I

T1

N0-1

M0

Stage II

T2

T3

N0-1

N0

M0

M0

Stage III

T3

T1-3

N1

N2

M0

M0

Stage IVA

T4

Any T

N0-2

N3

M0

M0

Stage IVB

Any T

Any N

M1

 

Pathological Stage Grouping (pTNM)

pT

pN

M

G

Location

Stage 0

T1s

N0

M0

n/a

Any

Stage IA

T1a

T1a

N0

N0

M0

M0

G1

GX

Any

Any

Stage IB

T1a

T1b

T1b

N0

N0

N0

M0

M0

M0

G2-3

G1-2

GX

Any

Any

Any

Stage IIA

T2

T2

T3

T3

N0

N0

N0

N0

M0

M0

M0

M0

G2-3

GX

G1-3

G1

Any

Any

Lower

Upper/middle

Stage IIB

T3

T3

T3

T3

N0

N0

N0

N1

M0

M0

M0

M0

G2-3

GX

Any

Any

Upper/middle

Lower/upper/middle

Location X

Any

Stage IIIA

T1

T2

N2

N1

M0

M0

Any

Any

Any

Any

Stage IIIB

T2

T3

T4a

N2

N1-2

N0-1

M0

M0

M0

Any

Any

Any

Any

Any 

Any

Stage IVA

T4a

T4B

Any T

N2

N0-2

N3

M0

M0

M0

Any

Any

Any

Any

Any 

Any

Stage IVB

Any T

Any N

M1

Any

Any

 

Postadjuvant Therapy (ypTNM)* Stage Grouping

yPT

yPN

M

Stage I

T0-2

N0

M0

Stage II

T3

N0

M0

Stage IIIA

T0-2

N1

M0

Stage IIB

T3

T0-3

T4a

N1

N2

N0

M0

M0

M0

Stage IVA

T4a

T4a

T4b

Any T

N1-2

NX

N0-2

N3

M0

M0

M0

M0

Stage IVB

Any T

Any N 

M1

* y indicates a pre-operative treatment was given

Adenocarcinoma Stage Grouping

Clinical Stage Grouping (cTNM)

cT

cN

M

Stage 0

T1s

N0

M0

Stage I

T1

N0

M0

Stage IIA

T2

N1

M0

Stage IIB

T2

N0

M0

Stage III

T2

T3

T4a

N1

N0-1

N0-1

M0

M0

M0

Stage IVA

T1-4a

T4b

Any T

N2

N0-2

N3

M0

M0

M0

Stage IVB

Any T

Any N

M1

 

Pathological Stage Grouping (pTNM)

pT

pN

M

G

Stage 0

T1a

N0

M0

N/A

Stage IA

T1a

T1a

N0

N0

M0

M0

G1

GX

Stage IB

T1a

T1b

T1b

N0

N0

N0

M0

M0

M0

G2

G1-2

GX

Stage IC

T1

T2

N0

N0

M0

M0

G3

G1-2

Stage IIA

T2

T2

N0

N0

M0

M0

G3

GX

Stage IIB

T1

T3

N1

N0

M0

M0

Any 

Any

Stage IIIA

T1

T2

N2

N1

M0

M0

Any 

Any

Stage IIIB

T2

T3

T4a

N2

N1-2

N0-1

M0

M0

M0

Any

Any

Any

Stage IVA

T4a

T4b

Any T 

N2

N0-2

N3

M0

M0

M0

Any

Any

Any

Stage IVB

Any T

Any N

M1

Any

 

Postadjuvant Therapy (ypTNM)* Stage Grouping

yPT

yPN

M

Stage I

T0-2

N0

M0

Stage II

T3

N0

M0

Stage IIIA

T0-2

N1

M0

Stage IIB

T3

T0-3

T4a

N1

N2

N0

M0

M0

M0

Stage IVA

T4a

T4a

T4b

Any T

N1-2

NX

N0-2

N3

M0

M0

M0

M0

Stage IVB

Any T

Any N 

M1

* y indicates a pre-operative treatment was given

Referencias

American Cancer Society, Esophagus Cancer, https://www.cancer.org/cancer/esophagus-cancer.html

NCCN Guidelines, Esophageal and Esophagastic Junction Cancers, V.1.2019, https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf(log in required).

SEER Statistics, Esophageal Cancer, https://seer.cancer.gov/statfacts/html/esoph.html

Burt, B. M., Groth, S. S., Sada, Y. H., Farjah, F., Cornwell, L., Sugarbaker, D. J., & Massarweh, N. N. (2017). Utility of Adjuvant Chemotherapy After Neoadjuvant Chemoradiation and Esophagectomy for Esophageal Cancer. Annals of Surgery.

D’Journo, X. B., & Thomas, P. A. (2014). Current management of esophageal cancer. Journal of Thoracic Disease6(2), S253-S264.

Haefner, M. F., Lang, K., Krug, D., Koerber, S. A., Uhlmann, L., Kieser, M., ... & Sterzing, F. (2015). Prognostic factors, patterns of recurrence and toxicity for patients with esophageal cancer undergoing definitive radiotherapy or chemo-radiotherapy. Journal of Radiation Research56(4), 742-749.

Kadri S, Lao-Sirieix P, O'Donovan M, et al. (2010). Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ, 341, c4372, c4667.

Keith, B. (2016). Esophageal Cancer. Mosby's Oncology Nursing Advisor: A Comprehensive Guide to Clinical Practice, 58.

Kutup, A., Nentwich, M. F., Bollschweiler, E., Bogoevski, D., Izbicki, J. R., & Hölscher, A. H. (2014). What should be the gold standard for the surgical component in the treatment of locally advanced esophageal cancer: transthoracic versus transhiatal esophagectomy. Annals of Surgery260(6), 1016-1022.

Napier, K. J., Scheerer, M., & Misra, S. (2014). Esophageal cancer: A Review of epidemiology, pathogenesis, staging workup and treatment modalities. World J Gastrointest Oncol6(5), 112-20.

Purim, O., Beny, A., Inbar, M., Shulman, K., Brenner, B., Dudnik, E., ... & Sarid, D. (2018). Biomarker-driven therapy in metastatic gastric and esophageal cancer: Real-life clinical experience. Targeted oncology, 1-10.

Roeder, F., Nicolay, N. H., Nguyen, T., Saleh-Ebrahimi, L., Askoxylakis, V., Bostel, T., ... & Huber, P. E. (2014). Intensity modulated radiotherapy (IMRT) with concurrent chemotherapy as definitive treatment of locally advanced esophageal cancer. Radiation Oncology9(1), 191.

Salehi, M., Moradi-Lakeh, M., Salehi, M. H., Nojomi, M., & Kolahdooz, F. (2013). Meat, fish, and esophageal cancer risk: a systematic review and dose-response meta-analysis. Nutrition Reviews71(5), 257-267.

Saltzman, J. R., Gibson, M. K., & Goldberg, R. M. (2018). Clinical manifestations, diagnosis, and staging of esophageal cancer. UpToDate, Waltham, MA.

Shaheen, N. J., Falk, G. W., Iyer, P. G., & Gerson, L. B. (2016). ACG clinical guideline: diagnosis and management of Barrett’s esophagus. The American Journal of Gastroenterology111(1), 30-50.

Spechler, S. J. (2013). Barrett esophagus and risk of esophageal cancer: a clinical review. JAMA310(6), 627-636.

Spechler, S. J., & Souza, R. F. (2014). Barrett's esophagus. New England Journal of Medicine371(9), 836-845.

Stahl M, Walz M, Stuschke M, et al. (2009). Phase III comparison of preoperative chemotherapy compared with chemoraditherpy in patients with locally advanced adenocarcinoma of the esophagogastric junction. Journal of Clinical Oncology, 27, 836.

Takeuchi, M., Suda, K., Hamamoto, Y., Kato, M., Mayanagi, S., Yoshida, K., ... & Takeuchi, H. (2018). Technical feasibility and oncologic safety of diagnostic endoscopic resection for superficial esophageal cancer. Gastrointestinal endoscopy88(3), 456-465.

Talukdar, F. R., di Pietro, M., Secrier, M., Moehler, M., Goepfert, K., Lima, S. S. C., ... & Herceg, Z. (2018). Molecular landscape of esophageal cancer: implications for early detection and personalized therapy. Annals of the New York Academy of Sciences1434(1), 342-359.

Tsottles, N.D. & Byrnes, P. (2011). Esophageal Cancer In Yarbro C.H, Wujcik, D. & Gobel, B.H. (2011). Cancer Nursing (pp. 1295-1315). Sudbury, MA: Jones and Bartlett.

Watanabe, M., Baba, Y., Nagai, Y., & Baba, H. (2013). Minimally invasive esophagectomy for esophageal cancer: an updated review. Surgery Today43(3), 237-244.

Palabras clave

Haga clic en cualquiera de estos términos para más artículos relacionados

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
R
S
T
U
V
X
Y
Z
#
 
A
B
C
E
F
G
H
K
L
M
N
O
P
R
S
T
U
V
 
 
Manténgase informado con las última información de OncoLink!   Suscribirse a los boletines electronico de OncoLink
Ver nuestros archivos de boletines